ArticleOpen forum infectious diseases2024
Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients.
Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- [Phase Ⅲ, multicenter, randomized, double-blinded, positive-controlled trial on the efficacy and safety of maribavir compared with valganciclovir in the treatment of post-transplant cytomegalovirus infection: Subgroup analysis of AURORA Trial in the Chinese population].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Trial
- Cytomegalovirus infections in thoracic organ transplant recipients: Updates on prevention, treatment, and immune monitoring.JHLT open · 2026Article
- Use of Maribavir in Adult Patients With Post-Transplant Refractory Cytomegalovirus Infection in the Real-Life Setting.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Real-World Use of Letermovir and Maribavir for CMV Prophylaxis and Treatment in Solid Organ Transplant Recipients: Clinical Outcomes and Resistance Patterns From a Dual-Center Cohort.Pharmacotherapy · 2025Article
- Optimizing maribavir management: The role of health system specialty pharmacies in access, monitoring, and waste reduction.Journal of managed care & specialty pharmacy · 2025Article
- Cytomegalovirus Retinitis in a Hematopoietic Stem Cell Transplant Recipient During Maribavir Pre-emptive Therapy.Infection & chemotherapy · 2025Article
- Article
- Evaluating Real-World Experience With Maribavir for Treatment of Refractory/Resistant Cytomegalovirus in Renal Transplant Recipients.Clinical transplantation · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
We evaluated use of maribavir (MBV) for treatment of 15 episodes of refractory/resistant cytomegalovirus infection in 13 solid organ transplant recipients. Treatment failure due to treatment-emergent MBV resistance or early virological recurrence after MBV discontinuation occurred in 7 (47%) episodes. Sustained viral clearance was achieved in 6 (40%) episodes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.